CLARIFICATION for Using C76.0 or C80.9 for Cases of Unknown Primary Involving Cervical Lymph Nodes

The AJCC introduced a new chapter, Chapter 6 – Cervical Lymph Nodes and unknown Primary Tumors of the Head and Neck, in the AJCC Cancer Staging Manual, 8th edition. Apparently, registrars are not sure how to use this chapter or which histologic types or subtypes are to be or not to be used with this primary site code or to TNM Stage using Chapter 6. Just because a person has a positive cervical lymph node biopsy does not mean that you can or should use Chapter 6 to stage the case or more importantly that you can assign the NOS H&N primary site code of C76.0 to the case.

Many if not most histologic types and subtypes do not fall into the criteria to allow use of C76.0 or AJCC Chapter 6 – and it is up to the registrar to know which do and which do not, so we can code site/histology/stage correctly for these special unknown primary tumors of the Head and Neck.

This chapter was designed to identify specific types of common Head and Neck cancers, not just any type of cancer, that is found in one or more cervical lymph nodes in the neck, but for which no primary site can be found – that is no primary site in the Head and Neck for Head and Neck cancers. Most cancers found in the head and neck that may metastasize to cervical lymph nodes are squamous cell carcinoma or salivary gland (adeno)carcinoma. There is actually a list of allowable histology codes in a table in Chapter 6 entitled; “Histology Codes” for reference.

(Continued on page 2)
We are finding registrars coding C76.0 for all kinds of cancers that are metastatic to cervical lymph nodes but are most likely cancers of the lung, breast, thyroid or colon that are metastatic to the neck or metastatic cancers from other (definitely not Head and Neck) anatomic site locations.

If a patient comes to your facility and only has an FNA or core or excisional biopsy of a cervical neck node but no other workup or scans or physical examination to try to identify the primary site – you do not automatically have a C76.0 primary…most of these neoplasms should be C80.9 – unknown. You should only be coding C76.0 as the primary site when it is highly likely that the patient has a head and neck cancer, not just a positive lymph node. Many of these cases will still be C80.9 unknown primary and not C76.0 unknown primary of the head and neck which indicates the tumor started in the head and neck and metastasized to the cervical node(s). Many other cancers can metastasize to cervical nodes than H&N cancers. The most likely candidates are breast and lung and thyroid. So, you have to look at all the information in the medical record to decide.

Small cell carcinoma, neuroendocrine carcinoma (low or high grade), malignant melanoma, Merkel cell carcinoma, lymphoma, sarcoma, clear cell carcinoma, signet ring cell carcinoma, germ cell tumors, GYN, and most mucinous neoplasms are not of head and neck origin – they start elsewhere and spread to the neck. And, special care should also be taken to ensure the metastatic squamous cell carcinoma is not of skin origin – because skin squamous cell carcinoma is not reportable – even when the neoplasm metastasizes to the cervical or other lymph nodes…it is still a skin cancer.

Please take care when assigning code C76.0 versus C80.9. These are different codes for specific reasons – and these neoplasms should not be mixed together. C76.0 should be reserved only for cancers that have nodal metastasis in the neck, biopsy proven, of usual head and neck histology. C80.9 should be used in all other cases when there is no primary tumor, but there are positive cervical lymph nodes. If all you have is a biopsy – use C80.9.
Leukemia & Lymphoma Society of Florida Blood Conference

The FCDS attended the Leukemia & Lymphoma Society Florida Blood Conference organized by the Leukemia and Lymphoma Society (LLS) in Fort Lauderdale at the Marriott Harbor Beach Resort & Spa on February 29th, 2020.

The Blood Conference is one of several conferences the FCDS attends annually as part of our Outreach Program. The FCDS reaches out to Florida communities, physicians and researchers to raise awareness of the state cancer registry, what its function is and how the data collected is used.

The Leukemia & Lymphoma Society® is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

The Florida Chapters of The Leukemia & Lymphoma Society hosted the event for blood cancer patients, survivors, family members, caregivers and healthcare professionals. Experts in the areas of blood cancer research, treatment and survivorship presented information on each of these topics including emerging therapies, treatment options and management of survivorship issues.
FCDS has noted a big increase in registrars making errors and omissions in the Patient Demographic Fields and Data. These fields and the data contained within these fields are critical to patient matching programs that FCDS uses every single day. As Social Security Numbers become less and less available, FCDS must rely more heavily on data contained in the 5 ‘name’ fields we collect, the date of birth, sex, race, Hispanic origin, and address fields. Additionally, the fields for height, weight and smoking history are heavily utilized by researchers and really need your attention.

Please make sure that you place the correct name in the correct field, Last Name, First Name, Middle Name/ Initial, Alias and Maiden Name. We are seeing far too many multiple last names in the last name field, multiple names in the first name field, middle initials in the first name field, etc. When this happens, patients don’t match up and we over-count cancers and persons with cancer in our state.

Please provide a ‘real’ Social Security Number when available. We know this is becoming more difficult in many registries.

Patient address fields are also a part of patient matching – but, play a lesser role than other patient identifiers.

Finally, the race, ethnicity, height, weight, and smoking fields are very important for reports and for researchers – they are used and we do pay attention to them when they are submitted as 999.

You will see these fields and unknown data displayed on the 2014-2018 Data Quality Indicator Report when you receive these in March 2020.

NONE of the FCDS-Required Fields are frivolous or ‘optional’. They are required for a reason…each and every one. Please adhere to the reporting requirements and provide FCDS with COMPLETE Abstracts – analytic or non-analytic – doesn’t matter.
**REMINDER:** DO NOT ENTER Unknown Primary in the Historical Grid

Registrars should not be submitting unknown primary (C809) of any histology as a Historical NED Case in the Historical Grid, except in very rare instances. The FCDS DAM states; “Historical Cases should not include Unknown Primary Cancers (C80.9 or C76.*).” The only new and still rare exception is C76.0 unknown primary of Head and Neck with ONLY positive cervical lymph nodes. And, even these cases are questionable as to whether they are skin cancer metastasis which would not be reportable or mucosal head and neck cancers with no evidence of a primary tumor.

FCDS does not edit these cases out because occasionally they are valid. However, there is a very real and valid reason for not including Unknown Primary in the Historical Grid. Unknown Primary Cancer indicates the patient has metastatic disease and no primary can be found. So, it is very rare that the Unknown Primary is ever truly free of disease. We do occasionally identify valid unknown primary cases with no evidence – rarely.

**Historical Grid cases MUST be cancers with NO EVIDENCE OF DISEASE.** They are historical in nature and are not active cancers.

An unknown primary implies the disease is continuously active and cannot be cured due to lack of evidence of where it even started.

How can you state with any confidence that an unknown primary is ever free of cancer when you don’t know where the cancer started or how widespread the disease actually is? It is contrary to what an unknown primary cancer with metastatic disease but no primary represents.

Again, Historical Grid case reports MUST be FREE OF ALL EVIDENCE OF CANCER to be reported in the Historical Grid…it is not a shortcut report.

This should be a very rare event…not to be used just when a registrar/abstractor has no information…the cancer must be NED…and it is contrary to rationale for unknown primary that it can be treated and the patient becomes evidence free if you don’t treat the primary tumor plus the metastasis. These cases should be few and far between…and not reported just because you lack the detailed information about cancer history.

*(Continued on page 6)*
ADDITIONALLY: Some histology(s) imply a primary site ‘default’ that should be used instead of C80.9 based on the histology. This is covered in the 2018 FCDS DAM under the Data Item, Primary Site on pages 95-96…and there is a table that should be used to identify a primary site with specific histology that should never be coded as C80.9 even when you don’t know where within that primary site rubric the cancer should be assigned.

2018 FCDS DAM - Section II - Page 95-96 is where this important reference can be found.

NOTE: THIS IS NOT A NEW CONCEPT OR RULE

Use the table below to assign primary site when the only information available is the histologic type of tumor and the patient has metastatic disease without an identifiable primary site. The primary site is presumed to be the NOS or “not otherwise specified” primary site code when the histology is known but for which no primary can be found. Do not code these cases to C80.9.

<table>
<thead>
<tr>
<th>Histologic Type Codes</th>
<th>Histologic Types</th>
<th>Preferred Site Codes for Ill-Defined Primary Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>8720-8790</td>
<td>Melanoma</td>
<td>C44._, Skin</td>
</tr>
<tr>
<td>8800-8811, 8813-8830,</td>
<td>Sarcoma except periosteal fibrosarcoma and dermatofibrosarcoma</td>
<td>C49._, Connective, Subcutaneous and Other Soft Tissues</td>
</tr>
<tr>
<td>8840-8921, 9040-9044</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8990-8991</td>
<td>Mesenchymoma</td>
<td>C49._, Connective Subcutaneous and Other Soft Tissues</td>
</tr>
<tr>
<td>8940-8941</td>
<td>Mixed tumor, salivary gland type</td>
<td>C07._ for Parotid Gland; C08._ for Other and Unspecified Major Salivary glands</td>
</tr>
<tr>
<td>9120-9170</td>
<td>Blood vessels tumors, Lymphatic vessel tumors</td>
<td>C49._, Connective Subcutaneous and other Soft tissues</td>
</tr>
<tr>
<td>9240-9252</td>
<td>Mesenchymal chondrosarcoma and giant cell tumors</td>
<td>C40.<em>, C41.</em> for bone and cartilage C49._, Connective, Subcutaneous, and Other Soft tissues</td>
</tr>
<tr>
<td>9580-9582</td>
<td>Granular cell tumor and alveolar soft part sarcoma</td>
<td>C49._, Connective, Subcutaneous and Other Soft Tissues</td>
</tr>
</tbody>
</table>
The Pat Strait Award for Excellence in Cancer Abstracting recognizes those individuals that contributed to a facility winning the Jean Byers Award by presenting a certificate to all its abstractors. The certificate is a way for FCDS to show our appreciation to those individuals that were responsible for helping a facility reach this exceptional quality standard.

We recognize that the facilities that achieve this high quality standard are staffed by exceptional professionals that made it possible for the facility to be awarded the Jean Byers Award.

The 2019 Pat Strait Award Winners are:

Joyce Allan       Heather Burner
Lori Allison      Julianne Campbell
Allissa Anderson  Sandra Carlson
Barbara Anderson  Kimberly Castaneda
Victor Angles     Magda Castro
Stacey Applegate  Kali Cerdan
Prudence Ashley   Curry Chapman
Marichu Auffenberg Kathie Churchill
Hector Aviles     Judith Clark
Karishma Banda    Sharon Clevenger
Leigh Bishop      Denise Colburn
Melissa Blakley   Colleen Condron
Lisa Borodemos    Katherine Cook
Krist Bowman      Nurgul Cooper
Bessie Brokenburr Henderson  Jennette Cox
Holly Brown      Charisse Creech
Jennifer Brown   Edna Cruet

(Continued on page 8)
Alicia Gassert  Barbara Lorentson  Joyce Newhouser
Ashley Giesecke  Janae Lott  Dawn Nguyen
Tammy Goas  Rosalba Marte  Carmen Nieves
Carol Hammond  Jessica Martin  Heidi Noell
Johanna Haneline  Keir Martin  Jennifer Nolte
Annette Harnage  Elizabeth Martinez  Leslie Nye
Vicki Hawhee  Dawn Mason  Mary Oleary
Stuart Herna  Mary Mason  Kari Oliger
Maggie Herrera  Celia Mathews  Laura Ortega
Megan Hoffmann  Nicola Mattis  Luz Ortizromero
Carol Hutchison  Penny May  Janice Pagano
Armand Ignacio  Krisha Mcdonald  Grace Patrick
Brigitte Johnson  Gladys Mejia  Sandra Pham
Joshua Johnson  Elizabeth Melendez  Peter Pierce
Jennie Jones  Pamela Melton  Maritza Polania
Patricia Jones  Dinah Merrill  Martina Price-Austin
Joyce Jones Pic  Julie Mierzejewski Yousif  Albert Reyes
Deborah Jordanreith  Jorge Migoya  Paula Riccio
Jennifer Kassan  Clarissa Moholick  Marie Romulus
Jacqueline Kenney  Maesidrisis Monte  Erica Santos
Katherine Khin  Susana Morales  Kathleen Saslow
Laura Kindergan  Karen Moulds  Deborah Schulte
Lisa Kofron  Carol Muir  Melissa Schuster
Tamara Lehman  Deborah Mulini  Ileeta Scolaro
Jennifer Lewis  Sue Neufeld  Adela Seidman
Deylis Sequeira

(Continued from page 7)
(Continued from page 8)

<table>
<thead>
<tr>
<th>Bubblela Simmons</th>
<th>Leann Tanaskovic</th>
<th>Judy Webber</th>
</tr>
</thead>
<tbody>
<tr>
<td>Darleen Small</td>
<td>Paulette Thomas</td>
<td>Janette Wienecke</td>
</tr>
<tr>
<td>Shauntel Smith</td>
<td>Sharon Thomas</td>
<td>Jennifer Wiggs</td>
</tr>
<tr>
<td>Tracy Smith</td>
<td>Ann Thompson</td>
<td>Jacqueline Williams</td>
</tr>
<tr>
<td>Susan Smith-pierce</td>
<td>Lisset Todd</td>
<td>Wendy Williams</td>
</tr>
<tr>
<td>Angie Straughn</td>
<td>Nancy Tucker</td>
<td>Nancy Wilson</td>
</tr>
<tr>
<td>Tammy Strickland</td>
<td>Roberto Urruchi</td>
<td>Janet Wyrick</td>
</tr>
<tr>
<td>Francis Suarez Penas</td>
<td>Monica Vasquez Olivas</td>
<td>Celia Zapata</td>
</tr>
<tr>
<td>Tina Swinney</td>
<td>Jennifer Vazquez</td>
<td>Jessica Zilke</td>
</tr>
<tr>
<td>Susan Smith-Pierce</td>
<td>Joyce Wallace</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lucas Wassira</td>
<td></td>
</tr>
</tbody>
</table>

Thank You

Data Visualization Dashboard

The FCDS has updated the Data Visualization Dashboard to include 2017 data. The dashboard has interactive incidence and mortality rates for the top cancers in Florida. Statistics are also available by state and county. Check it out at [https://fcds.med.miami.edu/inc/statistics_data_viz.shtml](https://fcds.med.miami.edu/inc/statistics_data_viz.shtml)
FCDS recognizes and presents the Jean Byers Award for Excellence in Cancer Registration each year to those facilities that have met or exceeded the national quality standards for timeliness and completeness in cancer reporting.

The Jean Byers Award is presented to any facility that meets the following criteria:

- All Deadlines met with respect to cancer case admissions and all cases reported to FCDS:
  - Annual Caseload Submission Deadline - June 30
  - Consolidated Follow Back Deadline - October 15
    - AHCA In Patient
    - AHCA AMBI
    - Death Certificate Notification
- No more than 5% (or 35 cases, whichever number is greater) of cancer case admissions reported to FCDS within 2 months (60 days) following the June 30 deadline
- No more than 10% of cancer case admission reported to FCDS within 12 months following the June 30 reporting deadline

The winners for 2019 (data admission year 2017) are:

1100-SHANDES UNIVERSITY OF FLORIDA
1170-N FLORIDA REGIONAL MEDICAL CENTER
1300-GULF COAST MEDICAL CENTER
1306-BAY MEDICAL CENTER
1505-CAPE CANAVERAL HOSPITAL
1508-PALM BAY HOSPITAL
1601-WESTSIDE REGIONAL MED CTR
1609-IMPERIAL POINT MEDICAL CENTER
1645-CORAL SPRINGS MEDICAL CENTER
1676-FLORIDA MEDICAL CENTER
1800-FAWCETT MEMORIAL HOSPITAL
1900-SEVEN RIVERS REGIONAL MEDICAL CTR
1905-CITRUS MEMORIAL HOSPITAL
2246-LAKE CITY MEDICAL CENTER
2304-AVENTURA HOSP AND COMP CANCER CTR
2310-ANNE BATES LEACH EYE HOSPITAL
2347-UNIVERSITY OF MIAMI HOSPITAL
2353-NORTH SHORE MEDICAL CENTER
2359-MIAMI CHILDRENS HOSPITAL
2372-U OF MIAMI HOSPITAL CLINICS
2638-ASCENSION ST. VINCENT'S RIVERSIDE
2647-NEMOURS CHILDRENS HOSPITAL
2660-ASCENSION ST. VINCENT'S SOUTHSIDE
2672-WOLFSON CHILDRENS HOSP NCC
2738-ASCENSION SACRED HEART

(Continued on page 11)
(Continued from page 10)

3300-ASCENSION SACRED HEART ON THE GULF
3701-OAK HILL HOSPITAL
3705-BAYFRONT HEALTH BROOKSVILLE
3906-TAMPA GENERAL HOSPITAL
3932-H LEE MOFFITT CANCER CENTER
4516-LEESBURG REGIONAL MEDICAL CENTER
4601-CAPE CORAL HOSPITAL
4605-LEE MEMORIAL HEALTH SYSTEM
4645-REG CANCER CTR GULF COAST HOSPITAL
4647-LEHIGH REGIONAL MEDICAL CENTER
4690-LEE MEMORIAL HOSPITAL HEALTHPARK
4770-CAPITAL REGIONAL MEDICAL CENTER
5100-BLAKE MEDICAL CENTER
5110-LAKEWOOD RANCH MEDICAL CENTER
5200-OCALA REGIONAL MEDICAL CENTER
5202-WEST MARION COMMUNITY HOSPITAL
5203-ASCENSION ST. VINCENT'S CLAY COUNTY
5205-ADVENTHEALTH OCALA
5607-NORTH OKALOOSA MEDICAL CENTER
5610-ASCENSION SACRED HEART EMERALD COAST
5705-RAULERSON HOSPITAL
5900-POINCIANA MEDICAL CENTER
5936-ST CLOUD REGIONAL MEDICAL CENTER
6003-DELRAY MEDICAL CENTER
6106-MORTON PLANT NORTH BAY HOSPITAL
6170-MEDICAL CENTER OF TRINITY
6201-NORTHSIDE HOSP HEART INSTITUTE
6249-MEASE DUNEDIN HOSPITAL
6251-ST ANTHONY HOSPITAL

6273-PALMS OF PASADENA HOSPITAL
6274-ST PETERSBURG GENERAL HOSPITAL
6278-MEASE COUNTRYSIDE HOSPITAL
6305-LAKELAND REGIONAL MEDICAL CENTER
6346-BARTOW REGIONAL MEDICAL CENTER
6348-LAKE WALES HOSPITAL
6570-FLAGLER HOSPITAL
6707-SANTA ROSA MEDICAL CENTER
6810-INGLEWOOD COMMUNITY HOSPITAL
6846-VENICE REGIONAL BAYFRONT HEALTH
7005-VILLAGES REGIONAL HOSPITAL
7446-ADVENTHEALTH FISH MEMORIAL

Congratulations!
Squamous Cell Carcinoma

8085 and 8086 can **ONLY** be used for Squamous Cell Carcinoma in a few H&N sites or they fail edits

**Oral Cavity**
- C01.9 - Base of Tongue
- C09.0 - Tonsillar Fossa
- C09.1 - Tonsillar Pillar
- C09.8 - Overlapping Lesion of Tonsil
- C09.9 - Tonsil, NOS

**Oropharynx (C10)**
- C10.0 – Vallecula
- C10.1 – Anterior Surface of Epiglottis
- C10.2 – Lateral Wall of Epiglottis
- C10.3 – Posterior Wall of Oropharynx
- C10.4 – Branchial Cleft
- C10.8 – Overlapping Lesion of Oropharynx
- C10.9 – Oropharynx, NOS

**Accessory Sinuses (C31)**
- C31.0 – Maxillary Sinus
- C31.1 – Ethmoid Sinus
- C31.2 – Frontal Sinus
- C31.3 – Sphenoid Sinus
- C31.8 – Overlapping Lesion of Accessory Sinuses
- C31.9 – Accessory Sinus, NOS

<table>
<thead>
<tr>
<th>Site remode</th>
<th>Site Description</th>
<th>Histology/Behavior</th>
<th>Histology/Behavior Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C019</td>
<td>BASE OF TONGUE</td>
<td>8085/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C019</td>
<td>BASE OF TONGUE</td>
<td>8086/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C090-C091,C098-C104,C108-C109</td>
<td>OROPHARYNX</td>
<td>8085/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C090-C091,C098-C104,C108-C109</td>
<td>OROPHARYNX</td>
<td>8086/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C111</td>
<td>POSTERIOR WALL OF NASOPH</td>
<td>8085/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C111</td>
<td>POSTERIOR WALL OF NASOPH</td>
<td>8086/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C310-C313,C318</td>
<td>SINUSES</td>
<td>8085/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C310-C313,C318</td>
<td>SINUSES</td>
<td>8086/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C319</td>
<td>ACCESSORY SINUS,NOS</td>
<td>8085/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
<tr>
<td>C319</td>
<td>ACCESSORY SINUS,NOS</td>
<td>8086/3</td>
<td>Squamous cell carcinoma, HPV– positive</td>
</tr>
</tbody>
</table>
Florida Registrars:

FCDS, like the rest of the country including the Florida Department of Health and the CDC, is closely monitoring daily updates on the COVID-19 (SARS-CoV-2) worldwide pandemic. The FCDS Annual Conference is not scheduled until late July. However, we feel it is important to initiate a conversation with the Florida Cancer Registry Community about pandemic response regarding the FCDS Annual Conference and other activities.

At this time, FCDS has no plans to cancel or reschedule the FCDS Annual Conference. However, FCDS will not make a final decision on whether or not we will move forward with our annual in-person meeting no later than June 30. FCDS is also looking into the possibility of providing alternate communications for important conference information and presentations via multiple 2-hour webcasts that you can view from home or office.

FCDS understands that some registrars have already completed conference registration including payment and hotel reservations. Should you change your mind about attendance or should FCDS cancel the entire conference – All FCDS Conference Registration Fees will be refunded.

Please do not schedule any non-refundable travel or accommodations for this conference until you receive final word from FCDS in blast email.

FCDS will be in regular communications with the registry community as FCDS, the Florida DOH, and the CDC monitor the pandemic situation.

We understand the next several weeks will be challenging for all and apologize for any inconvenience regarding finalizing plans for our conference.

The health and safety of our staff and all meeting attendees is of the utmost importance. FCDS working with DOH and the CDC will be doing our part to keep individuals within our community informed and in focus to help limit virus transmission or acquisition of this virus. FCDS and Florida DOH will not be ignoring public health warnings about the disease. We will keep our community as informed as possible regarding FCDS activities.

Thank you for your support…exercise precautions when meeting with other persons…and be safe and healthy.
Reportability

Question:
Patient had appendectomy in 2016 with low grade mucinous neoplasm, placed on observation after appendectomy. Now comes to our facility with ‘pseudomyxoma peritonei’ arising from the previous low grade mucinous neoplasm of the appendix. Is this recurrence reportable since it is stated to be arising from the previous appendix primary?

Answer:
We have consulted with SEER Staff to provide you with this answer. When a low grade mucinous neoplasm stated to be low grade pseudomyxoma peritonei behaves in malignant fashion with primary tumor T3 or higher and/or nodal metastasis and/or liver or other distant metastasis – the case is reportable as malignant mucinous adenocarcinoma of appendix. When the neoplasm recurs and is widespread, then this is a new primary – not the original not reportable low grade mucinous neoplasm of the appendix. The neoplasm has progressed to invasive cancer.

The low grade mucinous neoplasm of the appendix is a carcinoid…go ahead and report it…reason…because it is the carcinoid of the appendix that is the primary for the pseudomyxoma peritonei. Below is from: https://rarediseases.org/rare-diseases/pseudomyxoma-peritonei/

Pseudomyxoma peritonei is a rare malignant growth characterized by the progressive accumulation of mucus-secreting (mucinous) tumor cells within the abdomen and pelvis. The disorder develops after a small growth (polyp) located within the appendix bursts through the wall of the appendix, and spreads mucus-producing tumor cells throughout the surrounding surfaces (e.g., the membrane that lines the abdominal cavity [peritoneum]). As mucinous tumor cells accumulate, the abdominal area becomes swollen and digestive (gastrointestinal) function becomes impaired. Pseudomyxoma peritonei develops at a variable rate, but may grow at a slower rate (indolent) than other malignancies within the abdomen.

Frequently, the primary tumor that ruptured the appendix may be small in comparison to the extensive mucinous tumor that develops within the abdomen and pelvis.

(Continued on page 15)
The most common symptoms in individuals with pseudomyxoma peritonei occur due to progressively increasing mucinous tumor within the abdomen and pelvis. Usually, the most common symptom is increasing abdominal size (so called “jelly belly”) and abdominal discomfort from pressure. Although the abdomen may be swollen, it is generally not painful to touch (palpation).

An ovarian malignancy known as low malignant potential ovarian tumor may look similar to pseudomyxoma peritonei. However, this tumor remains as a solitary, expanding ovarian mass. It does not distribute itself around the abdomen, and should be distinguishable from pseudomyxoma peritonei. Symptoms may include abdominal or lower back pain. The exact cause of low malignant potential ovarian tumor is not known.

Mucinous cancers of the ovary, colon, stomach, and gallbladder may produce an excess of mucous in the abdominal cavity. These cancers are usually much more aggressive than the mucinous tumor from the appendix. They result in rapidly progressing accumulation of mucous in the abdominal region and intestinal obstruction. The exact cause of these tumors is not known.

Adenocarcinoid (goblet cell carcinoid) of the appendix is similar to pseudomyxoma peritonei. The mucinous tumor from the adenocarcinoid distributes itself around the abdomen in a very similar fashion to pseudomyxoma peritonei. However, this tumor is much more aggressive than the tumor in pseudomyxoma peritonei. Symptoms of this type of cancer often resemble those of acute appendicitis. The exact cause of adenocarcinoid of the appendix is not known.

The diagnosis of pseudomyxoma peritonei may be confirmed by radiologic technologies such as abdominal CT scan or abdominal MRI (magnetic resonance imaging). These imaging tests may reveal the characteristic distribution of large amounts of mucus to particular locations within the abdomen and pelvis. They may also localize a primary tumor in the area of the appendix referred to as a mucocoele.

The goal of the treatment of pseudomyxoma peritonei is cure. This is achieved in approximately 65% of patients. The treatments are cytoreductive surgery with peritonectomy in an attempt to remove all visible evidence of the-
disease from the abdomen and pelvis. Because the mucinous tumor is so widely distributed throughout the abdomen and pelvis, the surgery may take up to 12 hours. Then, to prevent reimplantation of cancer cells, the abdomen is washed with a warm chemotherapy solution. This is commonly referred to hyperthermic intraperitoneal chemotherapy or HIPEC. Sometimes the surgeon must search carefully for the primary appendiceal tumor for it may be very small in comparison to the mucinous tumor and mucinous ascites that can accumulate in kilogram quantities within the abdomen and pelvis. The hyperthermic intraperitoneal drugs which are commonly used to treat this disease include mitomycin C and oxaliplatin. The chemotherapy is heated to 42 degrees in the abdominal cavity to increase penetration of the drugs into the mucinous tumor and to increase the local cytotoxicity.

**Appendix Cancer/Pseudomyxoma Peritonei Research Foundation (ACPMP)**

Email: info@acpmp.org

Website: http://acpmp.org/

**NORD’s Rare Cancer Coalition (RCC)**

Email: Membership@RareDiseases.org

Website: https://rarediseases.org/get-involved/rare-cancer-coalition/

**Insular Thyroid Carcinoma**

**Question:**

A patient was diagnosed with poorly differentiated thyroid carcinoma; following our and Solid Tumor Rules ICD-O-3 as is our process we would code this to 8010/3 (carcinoma).
Chapter 73 of AJCC 8th edition lists poorly differentiated thyroid carcinoma as 8337/3 (insular carcinoma).

There is a question about grade that states poorly differentiated thyroid carcinoma is 837, and I know also that the forum does not determine histology.


Answer:

It is one of the topic areas that I have requested clarification from the NAACCR ICD-O Work Group (see entire list below where clarification for coding thyroid neoplasms is listed). We need to better understand thyroid reclassifications in the areas of the changes being made to tumor behavior, grade of tumor, nomenclature/terminology used to describe these tumors and more. Most of the changes are in the papillary and follicular thyroid carcinomas...but, some are in other thyroid carcinoma ‘types’ such as the one you describe here. The ICD-O-3.2 tables do have code 8337/3 as preferred code for the preferred term ‘poorly differentiated thyroid carcinoma (insular carcinoma). But, there are no Solid Tumor Rules to guide us to use this code and there has been no education/training on when to use or not use this code. I would say in this instance that code 8337/3 is correct (see excerpt from ICD-O-3.2 Table below)

The list of issues continues to grow – need rules, clarifications, neoplasm by histology reportable by program, AND staging rules for ALL - in writing;

- keratinizing SCCa/SCCa NOS – keratinizing SCCa – 8071/8070 – H&N Chapters - Keratinization in H&N Tumors is a prognostic indicator...those with keratinization (8071/3) have better prognosis and are less likely to have basaloid features and less likely to be HPV/P16 positive tumors...all leading to improved survival...but, we need to be sure keratinizing squamous cell is coded.

(Continued on page 18)
• NSCLC/Carcinoma, NOS – 8046/8010 – we still see in Florida about 1000 cases of NSCLC on path without further designation or testing – but, we cannot track the NSCLC anymore now that registrars are coding to 8010 to be able to TNM these cases.

• Coding Neuroendocrine Tumors and Neuroendocrine Carcinoma and Specified Subtypes – 8240/8246/all subtypes Coding Cholangiocarcinoma/Adenocarcinoma, NOS for hepatopancreatobiliary tumors.

• Coding Ductal adenocarcinoma/adenocarcinoma NOS for pancreatobiliary tumors

• 8504/2 intracystic (papillary) carcinoma – will this be site-restricted or site-associated or for both pancreas and breast?

• Invasive versus Noninvasive/In-situ versus benign and not reportable – thyroid and EUS diagnosed pancreatobiliary tumors without biopsy

• Need addition guidance on the Thyroid and Pancreas histology/behavior and reporting changes

• P16/HPV mediated – what a mess – and which sites can you use 8085/8086 and which cannot – and rules are different for coding histology than using chapters for P16 versus HPV-mediated.

• Clarify Classification and Reporting of CIN II becoming /2 – when and why? This has also come up with recent requests for our central registry to re-start capturing CIN II and CIN III and CIS of cervix which has been N/R since 1996. Confused and Concerned.

• Need to remind and promote changes in reporting Glomus Jugulare Tumors and Paraganglioma.

• Changes to Langerhans back to /1 (again) after changing to /3.

• Some of the lymphoproliferative disorders changing from /1 to /3 since we did it then pulled back and now we will change to /3 again. This will be confusing since only a few LPD will be reportable and most will not be reportable.

• Codes 8020/8021 of thyroid - allow both since registrars will continue to code both or restrict to 8020 or 8021 – and which one.

• Clarify use of code 8337/3 for thyroid carcinoma, poorly differentiated as identified in the ICD-O-3.2 tables – no STM instructions available.

• Use of 8148/2 and high grade glandular intraepithelial neoplasia of colon and the other 8148/2 conditions like esophageal, prostatic, biliary, esophageal or other glandular intraepithelial neoplasia grade III’s.
Site Help

Question:
Pathology states: left neck excision: mets carcinoma to a lymph node ... adenoid cystic carcinoma, 0.6cm, focally infiltrates a peripheral nerve
I originally used C05.0 - per the ICD book, it said with that histology use that site - CRStar won't take it
I asked my mentor for help I also used C11.1 and C06.9 and didn’t work.

Answer:
This case would qualify as C76.0 unknown head and neck primary because of the histology (adenoid cystic carcinoma) and the fact that there is a positive neck node and no evidence of a primary tumor with 8200/3 histology per the AJCC Cancer Staging Chapter 6 Histology Inclusion Table

It is probably a primary of the salivary glands or lacrimal gland or skin of the head and neck region – but, we cannot presume this with the limited information available on this case.

Adenoid cystic carcinoma is a cancer of secretory glands…but, you have secretory glands all over the place – glands that secrete something. So, a positive neck node hints at a salivary gland or lacrimal gland primary or even a skin of head and neck primary. But, we cannot make an assumption based only on this limited amount of information. But, we now allow for C76.0 for specific histologies that meet specific criteria – and this case does qualify based on positive neck node and the histologic type identified.
NAACCR SURVEY COURSE: UNDERSTANDING POPULATION-BASED
CANCER REGISTRIES COURSE


The NAACCR Survey Course is a self-paced web-based learning series aimed at broadening the student’s understanding of Population-Based Cancer Registries (aka; Central Cancer Registries). The series consists of four (4) topic areas with multiple modules under each topic. Each module was developed by NAACCR members who are recognized experts on the topic they present. Each module consists of a short recording and slides associated with the recording. Topics are periodically updated as necessary. We recently added the seven (7) modules under Data Management modules 1-7.

This self-paced series is about Central Cancer Registry Practices in general and are not specific to Florida or any hospital specific requirements.

The modules are free and are available to anyone with a MyNAACCR account! Just click on the link above and login.

The course does help fill in some of the blanks where hospital and central registries diverge and helps the student to better understand ‘why’ central cancer registries operate the way they do in conjunction with hospitals and health departments – and to help the abstractor/registrar/manager see the bigger picture.

If you have any questions or comments, you can leave them in the discussion tab.

Introduction to Cancer Registries and Cancer Surveillance

1. Public Health Surveillance Introduction & Fundamentals
2. Establishing an Effective Population-based Cancer Registry System

(Continued on page 21)
Registry Operations

1. Casefinding
2. Follow-up
3. Data Editing
4. Record consolidation
5. Death clearance

Registry Management

1. Registry Development
2. Data Quality and Completeness
3. Ethics & confidentiality
4. Data Management – IT resources
   - Module 1 – Course Introduction
   - Module 2 – Managing Central Registry’s Data
   - Module 3 – Infrastructure
   - Module 4 – Security
   - Module 5 – Electronic Documents and Standards
   - Module 6 – Interoperability
   - Module 7 – Registry of the Future
   - Module 8 – Course Summary

Uses of Population-Based Registry Data

1. Calculation and Assessment of Survival Rates
2. Calculation and Assessment of Cancer Incidence
3. Using Central Cancer Registry Data for Cancer Control and Cancer Research

Angela Martin
amartin@naaccr.org

Jim Hofferkamp
jhofferkamp@naaccr.org
To Our Florida Cancer Registrars:

NAACCR has always encouraged participants to view their live webinars in a group setting.

However, due to the current situation with COVID-19 viewing the webinars as a group is not recommended.

FCDS recommends that ALL 7 Florida Host Facilities and ALL Individual Florida Cancer Registrars who attend NAACCR Webinars occasionally or routinely view the recorded sessions via FLccSC rather than attending in small or large groups, individually registering for each webinar, or overwhelming NAACCR with Florida Registrations. FCDS does not want to confuse or complicate how FCDS pays for your attendance at one or more NAACCR Webinars in group settings. Individual registrations will be confusing, cumbersome, and you may be charged for attendance.

You will not be able to register for upcoming NAACCR Webinars on the FCDS website until further notice…we have removed all registrations.

FCDS will continue to provide the webinar series – but, only in recorded sessions. You MUST be registered in both IDEA and FLccSC to view the recordings. You may view recorded NAACCR Webinars via FLccSC 24 hours a day, 7 days a week – from your desktop at home or in your office.

It may take up to 2 weeks following the ‘live’ NAACCR Webinar for FCDS to obtain the recording links and all webinar materials and to get them posted on FLccSC. So, please be patient…the recordings and materials will be posted in FLccSC as soon as NAACCR makes them available to FCDS.

If you are not already a registered FLccSC User – please follow the instructions below to get signed up. You must have an FCDS IDEA Account, first.

FCDS encourages ALL Florida Registrars access FLccSC via your personal FCDS IDEA Account and use the Education/Training Tab to automatically redirect your access to the FLccSC Learning Management System. This way our two systems (IDEA and FLccSC) can communicate with one another.

(Continued on page 23)
FCDS will continue to provide education and training during these difficult times. However, how we will be providing information, education and training using electronic communications until the COVID-19 crisis has passed or until further notice. So, please read ALL emails that come from FCDS regularly – or you will be out of touch with important FCDS Information, Conferences, Webinars, Updates, etc. Email is very important today.

1. **Create an FCDS IDEA User Account** by clicking on the FCDS IDEA icon from the main FCDS webpage. Follow the onscreen instructions to Create New User.

   a. Your new FCDS IDEA Account will give you minimal privileges in the FCDS IDEA secure data sharing portal – and is your direct access into FLccSC, Florida’s online learning management system. It is also where you can be granted access permission to work on hospital-specific data or cases – or to upload batches of cases.

   b. FCDS IDEA is also where you can directly access FLccSC, Florida’s learning management system – which houses the NAACCR Webinar Recording Links and CEU Quiz Links, FCDS Abstractor Code Test, FCDS Webcast Recordings and CEU Quizzes, and other cancer registry training ‘courses’.

   c. Remember the email address you are using to create your FCDS IDEA User Account – you will need the same email address to create a FLccSC User Account.

2. **To get into FLccSC from FCDS IDEA** - you first login to FCDS IDEA, then go to the Education/FCDS Tools menu in IDEA and click on the FLccSC – Learning Management System menu selection.

   FLccSC is a separate software that is linked to FCDS IDEA and is where you will find the NAACCR Webinar Recording Links and CEU Quiz Links, FCDS Abstractor Code Test, FCDS Webcast Recordings and CEU Quizzes, and several other cancer registry training ‘courses’. The ‘courses’ are grouped by Category to help you locate specific ‘courses’. Once you are in the FLccSC System – you can view courses, enroll in courses, take courses, take quizzes, and get CEU Certificates.

3. **Once you are in the FLccSC system** – you will need to create a FLccSC Account. You MUST use the same email address to register in FLccSC that you used for your FCDS IDEA registration.

   a. If you do not use the same email address – the two systems get confused and cannot track you.

   b. Once you are registered, it is easy to go back and forth between FCDS IDEA and FLccSC using the FCDS IDEA Menu selection under Education / FCDS Tools.

4. Following approval of new user accounts – you should now be able to see and access “Available Courses”

5. Click on the ‘course’ or ‘webinar’ you wish to take and ‘enroll’ in the ‘course’ to get started.

6. Follow the Instructions all the way until you take & pass the test – and can print a Certificate of Completion as available.

If you have any questions, please contact Steven Peace @ FCDS – 305-243-4601 or speace@med.miami.edu
NAACCR Cancer Registry and Surveillance Webinar Series Registration

The Florida Cancer Data System is happy to announce that for another year we will be presenting the NAACCR Cancer Registry and Surveillance Webinar. Seven Florida facilities will host the 2019-2020 webinar series. Be sure to mark your calendars for each of these timely and informative NAACCR webinars.

- Boca Raton Regional Hospital (Boca Raton)
- Moffitt Cancer Center (Tampa)
- M.D. Anderson Cancer Center Orlando (Orlando)
- Shands University of Florida (Gainesville)
- Gulf Coast Medical Center (Panama City)
- Baptist Regional Cancer Center (Jacksonville)
- Florida Cancer Data System (Miami)

*** In person attendance cancelled until further notice. Please Login to FCDS IDEA->Education->FLccSC Learning Management 2 weeks after webinar to watch recordings and get CEUs ***

Special thanks to the hosting facilities for their participation and support. For a complete description of the webinars, click here: https://fcds.med.miami.edu/scripts/naaccr_webinar.pl. All webinars start at 9am.

Please go to the FCDS website to register online for your location of choice. Registration link is: https://fcds.med.miami.edu/scripts/naaccr_webinar.pl. A separate registration will be required for each webinar. The number of participants allowed to be registered for each webinar will be dependent on space availability. For more information, please contact Steve Peace at 305-243-4601 or speace@med.miami.edu.

<table>
<thead>
<tr>
<th>DATE</th>
<th>TOPIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>*10/3/19</td>
<td>Breast 2019</td>
</tr>
<tr>
<td>*11/7/19</td>
<td>Bladder and Kidney 2019</td>
</tr>
<tr>
<td>*12/5/19</td>
<td>Base of Tongue 2019</td>
</tr>
<tr>
<td>*1/09/20</td>
<td>Prostate 2020</td>
</tr>
<tr>
<td>*2/6/20</td>
<td>SSDIs an In-Depth Look</td>
</tr>
<tr>
<td>*3/5/20</td>
<td>Abstracting and Coding Boot Camp 2020</td>
</tr>
<tr>
<td>4/2/20</td>
<td>Melanoma 2020</td>
</tr>
<tr>
<td>5/7/20</td>
<td>Central Nervous System 2020</td>
</tr>
<tr>
<td>6/11/20</td>
<td>Esophagus 2020</td>
</tr>
<tr>
<td>7/9/20</td>
<td>Navigating the 2020 Survey Application Record (SAR)</td>
</tr>
<tr>
<td>8/6/20</td>
<td>Corpus Uteri 2020</td>
</tr>
<tr>
<td>9/3/20</td>
<td>Coding Pitsfalls 2020</td>
</tr>
</tbody>
</table>

Please go to the FCDS website to register online for your location of choice. Registration link is: https://fcds.med.miami.edu/scripts/naaccr_webinar.pl. A separate registration will be required for each webinar. The number of participants allowed to be registered for each webinar will be dependent on space availability. For more information, please contact Steve Peace at 305-243-4601 or speace@med.miami.edu.
Florida Cancer Data System
Cancer Reporting Completeness Report

TOTAL NUMBER OF CASES IN THE FCDS MASTERFILE AS OF MARCH 31, 2020

Total number of New Cases added to the FCDS Master file in March 2020: 47,608

Did you know that FCDS Webcasts and NAACCR Webinars can be viewed after-the-fact? FCDS Webcasts and NAACCR Webinars are recorded and posted on the FCDS Website (Education Tab). The FCDS Webcast recordings are available free of charge and can be viewed anytime/anywhere by anybody. However, starting in October 2017 the CEU award mechanism is restricted to approved FLccSC Users. Access to the NAACCR recordings is still password protected.

Recordings of FCDS Webcasts held 2014-2017 can be accessed from the FCDS Website. There are no CEU Quizzes for sessions held 10/2014-9/2017. However, your attendance must be manually logged into the FCDS CEU Tracking System for you to get credit for attending these recorded sessions.

Recordings of FCDS Webcasts held 10/2017 or later can be viewed either from the FCDS Website or in FLccSC, Florida’s new Learning Management System. However, Registrars must have an active FLccSC Account and must take and pass the CEU Quiz to get any CEUs and to obtain a certificate of attendance. NAACCR Webinars have their own CEU award mechanism whether viewed live or via a recorded session. Again, access to the NAACCR recordings is password protected. Only Florida registrars with Active/Current FCDS Abstractor Codes can access NAACCR Webinars per FCDS/NAACCR agreement.

Please contact FCDS for more information on viewing recorded webinars, or to obtain the password to view individual NAACCR Webcast Recordings.

Missed an FCDS or NAACCR Webinar?